Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy

Radiother Oncol. 2022 Jan;166:88-91. doi: 10.1016/j.radonc.2021.11.012. Epub 2021 Nov 25.

Abstract

The immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive conditions. Antibody testing may be useful to identify candidates for additional vaccine doses.

Keywords: COVID-19; Immunogenicity; Lung cancer; Radiotherapy; SARS-CoV-2; mRNA vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Neoplasms* / radiotherapy
  • Prospective Studies
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine